ArticleCNS neuroscience & therapeutics2026
Admission Phenotype Clarifies the Apparent Prognostic Contrast Between TOAST Etiologic Subtypes in Large-Core Anterior-Circulation Large-Vessel Occlusion.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveIn large-core anterior-circulation large-vessel occlusion (LVO), differing admission clinical-imaging profiles complicate interpretation of prognostic differences between large-artery atherosclerosis (LAA) and cardioembolism (CE). We assessed whether these differences persisted after adjustment and whether endovascular thrombectomy (EVT)-outcome associations differed by etiology.
methodsWe analyzed 631 patients with Alberta Stroke Program Early CT Score (ASPECTS) ≤ 5 from the 38-center MAGIC registry; 404 underwent EVT plus medical therapy and 227 received medical therapy alone. The primary outcome was 90-day modified Rankin Scale (mRS) 0-3. Mixed-effects models assessed etiology-outcome associations and treatment-by-etiology interaction. Among EVT-treated patients, Shapley decomposition quantified domain contributions to attenuation of the LAA-CE contrast.
resultsAmong EVT-treated patients, higher crude odds of mRS 0-3 with LAA (OR 1.59, 95% CI 1.05-2.42) were substantially attenuated after adjustment (aOR 0.92, 95% CI 0.53-1.59). No adjusted LAA-CE contrast was evident with medical therapy alone (aOR 1.12, 95% CI 0.47-2.65). In a separate fixed-effects decomposition model, the absolute log-odds contrast was attenuated by 96.2% after inclusion of measured pretreatment domains, with imaging/collateral features, demographics, and stroke severity contributing most. For the secondary mRS 0-2 outcome, adjusted odds favored CE (aOR 0.46, 95% CI 0.25-0.84). No treatment-by-etiology interaction was detected (p = 0.944).
interpretationAdmission clinical-imaging phenotype clarified the apparent LAA-CE prognostic contrast and may help reconcile discordant findings across EVT cohorts. These findings reinforce established clinical-imaging criteria as the basis for hyperacute EVT selection rather than LAA versus CE etiology alone.
trial registrationChinese Clinical Trial Registry (ChiCTR.org.cn); ChiCTR2100051664; https://www.chictr.org.cn/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.